A S Meijnikman1,2, C E M De Block1,2, E Dirinck2, A Verrijken1,2, I Mertens2, B Corthouts3, L F Van Gaal1,2. 1. University of Antwerp, Department of Medicine, Antwerp, Belgium. 2. Department of Endocrinology, Diabetology & Metabolism, Antwerp University Hospital, Edegem, Belgium. 3. Department of Radiology, Antwerp University Hospital, Edegem, Belgium.
Abstract
OBJECTIVE: Type 2 diabetes (T2DM) is known to be underdiagnosed. Tests for diagnosis include fasting plasma glucose (FPG), oral glucose tolerance test (OGTT) and HbA1c. HbA1c can be tested in non-fasting conditions. Therefore, general practitioners almost no longer execute OGTT's. We evaluated the performance of OGTT versus HbA1c in a population consisting of overweight and obese subjects, which can be considered a 'high risk' population. RESEARCH DESIGN AND METHODS: A total of, 1241 overweight and obese subjects without a history of diabetes (male/female: 375/866, age 44±13 years, body mass index 38.0±6.1 kg m-2) were tested for glucose tolerance status using FPG, OGTT and HbA1c. RESULTS: Exactly, 46.8% were found to have prediabetes and 11.9% were newly diagnosed with T2DM (male/female=18.9/8.9%) using ADA criteria. Testing only HbA1c would have resulted in 78 subjects being diagnosed with T2DM, but 47.3% of newly diagnosed patients would have been missed if OGTT would not have been done. Exactly 581 subjects were diagnosed with prediabetes, 1.4% subjects had impaired fasting glucose (IFG) 30.5% had impaired glucose tolerance (IGT), 5.1% subjects had a combined IFG+IGT, and 9.8% had an isolated elevated HbA1c (5.7-6.4%). Of the 581 subjects with prediabetes, 257 had an HbA1c <5.7%. Therefore, 44.2% subjects would have been missed when OGTT would not have been done. CONCLUSION: In a population with only overweight and obese adult subjects, 46.8% were diagnosed with prediabetes and 11.9% were newly diagnosed with diabetes. Exactly, 5.6 and 20.7% of total population met the diagnostic criteria of the OGTT for diabetes and prediabetes, respectively, but did not meet the diagnostic criteria of the HbA1c. These data suggest that not performing an OGTT results in significant underdiagnose of T2DM in an overweight and obese adult population.
OBJECTIVE:Type 2 diabetes (T2DM) is known to be underdiagnosed. Tests for diagnosis include fasting plasma glucose (FPG), oral glucose tolerance test (OGTT) and HbA1c. HbA1c can be tested in non-fasting conditions. Therefore, general practitioners almost no longer execute OGTT's. We evaluated the performance of OGTT versus HbA1c in a population consisting of overweight and obese subjects, which can be considered a 'high risk' population. RESEARCH DESIGN AND METHODS: A total of, 1241 overweight and obese subjects without a history of diabetes (male/female: 375/866, age 44±13 years, body mass index 38.0±6.1 kg m-2) were tested for glucose tolerance status using FPG, OGTT and HbA1c. RESULTS: Exactly, 46.8% were found to have prediabetes and 11.9% were newly diagnosed with T2DM (male/female=18.9/8.9%) using ADA criteria. Testing only HbA1c would have resulted in 78 subjects being diagnosed with T2DM, but 47.3% of newly diagnosed patients would have been missed if OGTT would not have been done. Exactly 581 subjects were diagnosed with prediabetes, 1.4% subjects had impaired fasting glucose (IFG) 30.5% had impaired glucose tolerance (IGT), 5.1% subjects had a combined IFG+IGT, and 9.8% had an isolated elevated HbA1c (5.7-6.4%). Of the 581 subjects with prediabetes, 257 had an HbA1c <5.7%. Therefore, 44.2% subjects would have been missed when OGTT would not have been done. CONCLUSION: In a population with only overweight and obese adult subjects, 46.8% were diagnosed with prediabetes and 11.9% were newly diagnosed with diabetes. Exactly, 5.6 and 20.7% of total population met the diagnostic criteria of the OGTT for diabetes and prediabetes, respectively, but did not meet the diagnostic criteria of the HbA1c. These data suggest that not performing an OGTT results in significant underdiagnose of T2DM in an overweight and obese adult population.
Authors: Lars Rydén; Peter J Grant; Stefan D Anker; Christian Berne; Francesco Cosentino; Nicolas Danchin; Christi Deaton; Javier Escaned; Hans-Peter Hammes; Heikki Huikuri; Michel Marre; Nikolaus Marx; Linda Mellbin; Jan Ostergren; Carlo Patrono; Petar Seferovic; Miguel Sousa Uva; Marja-Riita Taskinen; Michal Tendera; Jaakko Tuomilehto; Paul Valensi; Jose Luis Zamorano; Jose Luis Zamorano; Stephan Achenbach; Helmut Baumgartner; Jeroen J Bax; Héctor Bueno; Veronica Dean; Christi Deaton; Cetin Erol; Robert Fagard; Roberto Ferrari; David Hasdai; Arno W Hoes; Paulus Kirchhof; Juhani Knuuti; Philippe Kolh; Patrizio Lancellotti; Ales Linhart; Petros Nihoyannopoulos; Massimo F Piepoli; Piotr Ponikowski; Per Anton Sirnes; Juan Luis Tamargo; Michal Tendera; Adam Torbicki; William Wijns; Stephan Windecker; Guy De Backer; Per Anton Sirnes; Eduardo Alegria Ezquerra; Angelo Avogaro; Lina Badimon; Elena Baranova; Helmut Baumgartner; John Betteridge; Antonio Ceriello; Robert Fagard; Christian Funck-Brentano; Dietrich C Gulba; David Hasdai; Arno W Hoes; John K Kjekshus; Juhani Knuuti; Philippe Kolh; Eli Lev; Christian Mueller; Ludwig Neyses; Peter M Nilsson; Joep Perk; Piotr Ponikowski; Zeljko Reiner; Naveed Sattar; Volker Schächinger; André Scheen; Henrik Schirmer; Anna Strömberg; Svetlana Sudzhaeva; Juan Luis Tamargo; Margus Viigimaa; Charalambos Vlachopoulos; Robert G Xuereb Journal: Eur Heart J Date: 2013-08-30 Impact factor: 29.983
Authors: Carlos Lorenzo; Lynne E Wagenknecht; Anthony J G Hanley; Marian J Rewers; Andrew J Karter; Steven M Haffner Journal: Diabetes Care Date: 2010-06-23 Impact factor: 19.112
Authors: Mustafa Kanat; Diedre Winnier; Luke Norton; Nazik Arar; Chris Jenkinson; Ralph A Defronzo; Muhammad A Abdul-Ghani Journal: Diabetes Care Date: 2011-02-23 Impact factor: 19.112
Authors: Tien Y Wong; Gerald Liew; Robyn J Tapp; Maria Inês Schmidt; Jie Jin Wang; Paul Mitchell; Ronald Klein; Barbara E K Klein; Paul Zimmet; Jonathan Shaw Journal: Lancet Date: 2008-03-01 Impact factor: 79.321
Authors: Michael Bergman; Muhammad Abdul-Ghani; João Sérgio Neves; Mariana P Monteiro; Jose Luiz Medina; Brenda Dorcely; Martin Buysschaert Journal: J Clin Endocrinol Metab Date: 2020-08-01 Impact factor: 5.958
Authors: P Kaitlyn Edelson; Kaitlyn E James; Aaron Leong; Juliana Arenas; Melody Cayford; Michael J Callahan; Sarah N Bernstein; Jessica Sheehan Tangren; Marie-France Hivert; John M Higgins; David M Nathan; Camille E Powe Journal: J Clin Endocrinol Metab Date: 2020-05-01 Impact factor: 5.958
Authors: Vanessa Guerreiro; Isabel Maia; João Sérgio Neves; Daniela Salazar; Maria João Ferreira; Fernando Mendonça; Maria Manuel Silva; Marta Borges-Canha; Sara Viana; Cláudia Costa; Jorge Pedro; Ana Varela; Eva Lau; Paula Freitas; Davide Carvalho Journal: Diabetol Metab Syndr Date: 2022-07-06 Impact factor: 5.395
Authors: Yiling J Cheng; Alka M Kanaya; Maria Rosario G Araneta; Sharon H Saydah; Henry S Kahn; Edward W Gregg; Wilfred Y Fujimoto; Giuseppina Imperatore Journal: JAMA Date: 2019-12-24 Impact factor: 56.272
Authors: Bahira Shahim; Viveca Gyberg; Dirk De Bacquer; Kornelia Kotseva; Guy De Backer; Oliver Schnell; Jaakko Tuomilehto; David Wood; Lars Rydén Journal: Cardiovasc Diabetol Date: 2018-01-24 Impact factor: 9.951
Authors: Rohit Babbar; Martin Heni; Andreas Peter; Martin Hrabě de Angelis; Hans-Ulrich Häring; Andreas Fritsche; Hubert Preissl; Bernhard Schölkopf; Róbert Wagner Journal: Front Endocrinol (Lausanne) Date: 2018-03-19 Impact factor: 5.555